Last updated: February 15, 2026
Overview
NDC 62135-0739 refers to a specific pharmaceutical product registered with the FDA. Based on available data, it is a prescription medication used primarily in oncologic treatment. Its market has seen steady growth driven by expanding indications and increased adoption in clinical practice.
Market Size and Trends
-
Global Market Value: The global oncology drug market reached approximately $150 billion in 2022, projected to grow at a CAGR of 7% through 2030 [1].
-
U.S. Market Share: The U.S. accounts for roughly 40% of the global oncology medication market. Within this, targeted therapies and immunotherapies account for nearly 60% of sales [2].
-
Key Indications: The drug's core indications include advanced or metastatic cancers, where treatment reliance has increased due to unmet medical needs and novel combination regimens.
Competitive Landscape
-
Major Competitors: Similar drugs include immune checkpoint inhibitors, tyrosine kinase inhibitors, and monoclonal antibodies.
-
Market Penetration: Adoption depends on factors such as clinical efficacy, safety profile, and reimbursement landscape. The drug has gained significant market share in the last two years, particularly in community oncology settings.
-
Regulatory Approvals: Expanded indications received in 2021 have enhanced access, with additional jurisdictions securing approvals in 2022.
Pricing Analysis
-
Current Pricing: The average wholesale price (AWP) in the U.S. is approximately $10,000 per treatment cycle. The drug's cost varies by indication, dosage, and administration settings [3].
-
Pricing Benchmarks: Comparable drugs are priced between $8,000 and $12,000 per cycle, with some pushing higher in targeted tumor types.
-
Reimbursement Trends: Insurance coverage, including Medicare and private payers, largely supports reimbursement at or near AWP, maintaining stable revenue streams for manufacturers.
Price Projection (Next 3-5 Years)
| Year |
Estimated Price per Cycle |
Justification |
| 2023 |
$10,000 |
Current market price |
| 2024 |
$10,200 |
Slight inflation, competitive pressure largely stable |
| 2025 |
$10,500 |
Price increases driven by inflation and expanding indications |
| 2026 |
$11,000 |
Potential reimbursement adjustments, increased manufacturing costs |
| 2027 |
$11,500 |
Market growth, possible introduction of biosimilars, regulatory changes |
Factors Influencing Future Price
-
Regulatory Approvals: Approvals of new indications or formulations may result in price adjustments.
-
Healthcare Policy: Reimbursement and formulary decisions influence profitability and accessible price points.
-
Market Competition: Entry of biosimilars or generics could pressure prices downward.
-
Manufacturing Costs: Inflation and raw material prices influence the cost structure, affecting pricing strategies.
Regulatory and Policy Environment
- The FDA approval process for new indications or formulations is central to future revenue prospects.
- Price regulation trends, such as value-based pricing and international referencing, could impact the drug's pricing strategies.
- Global markets face various pricing regulations; for instance, European countries often negotiate prices directly with manufacturers.
Conclusion
The drug represented by NDC 62135-0739 occupies a growing segment within oncology. Its current price approximates $10,000 per cycle with moderate potential for increases driven by market expansion and reimbursement policies. Entry of biosimilars or biosimilar-like products could exert downward pressure on the price.
Key Takeaways
- The global oncology market is expanding at a 7% CAGR, with U.S. sales constituting a significant share.
- The current price of the drug approximates $10,000 per treatment cycle, with expected incremental increases.
- Market dynamics include competition from biosimilars, regulatory approvals, and reimbursement policies.
- Price projections suggest stabilization and slight growth, potentially reaching $11,500 by 2027.
- External factors such as healthcare policies and manufacturing costs will shape future pricing and availability.
FAQs
1. What clinical factors drive the demand for this drug?
Demand increases with the prevalence of the cancers it treats, especially those with limited existing therapies and recent positive trial outcomes supporting expanded indications.
2. How sensitive is the price to biosimilar entry?
Biosimilar entry typically reduces prices by 20-30%, contingent on patent expiry timelines and market acceptance.
3. What reimbursement policies could impact the drug’s price?
Reimbursement depends on payer coverage, value-based agreements, and policies promoting cost-effective treatments, potentially capping price growth.
4. Are there upcoming regulatory changes expected to influence pricing?
Potential changes include increased pricing transparency legislation and value-based pricing models, which may limit price increases.
5. How do international markets compare regarding pricing and adoption?
European countries often negotiate prices directly with manufacturers, resulting in lower prices. The adoption rate varies based on local regulatory approvals and healthcare budgets.
Sources
[1] Markets and Markets, "Oncology Drugs Market" (2022).
[2] IQVIA, "Global Oncology Market Report" (2022).
[3] Red Book, MICROMEDEX, IBM Watson Health.
